No Detail Found!

Expressions of CD80 and CD86 in Cancer Patients and Its Prognostic Significance

Author(s)
Athraa Ismael Department of Biology, College of Sciences, University of Kirkuk,Kirkuk,Iraq
Shilan Jabbar Department of Biology, College of Sciences, University of Kirkuk,Kirkuk,Iraq
Abstract
Background: Strategies for modulating the tumor microenvironment (TME) have opened up new treatment paths in various malignancies, with dramatic but variable intertemporal success. Consequently, studying TME's molecular players may aid in understanding how tumor cells and TME interact. Tumor cells and infiltrative tumor lymphocytes express immune checkpoint proteins, including Cluster of Differentiation 80 (CD80) and CD86 on their surface. CD80 and CD86 are members of the immunoglobulin superfamily (IgSF). The costimulatory protein CD28, which is present on the outermost portion of all T cells, and the inhibitory receptor CTLA-4 (cytotoxic T-lymphocyte antigen-4, also known as CD152) are ligands for CD86 and CD80. CD28 and CTLA-4 have essential yet opposing functions in T cell activation. T-cell responses are stimulated when they bind to CD28 but suppressed when they connect to CTLA-4. Aim of the study: The goal was to determine how much the CD80 and CD86 genes were expressed genetically in vfie blood malignancies and ten solid tumors. Methods: Clinical specimens were collected from patients with different cancers attending Kirkuk Oncology Centre. Patients were categorized into two main groups: the solid tumor group and Blood derived cancer group alongside their control counterparts. The study investigated the genetic expression of the CD80 and CD86 genes using q RT-PCR technologies. Results: Using q RT- PCR, we measured the expression of a gene CD80 /CD86. The results showed different levels of elevation in patient samples of solid and hematological tumors, which were compared with the control group for this study. First, evaluation of this marker CD80/CD86 in solid tumors showed a significant increase in patients with brain cancer compared to their counterparts in the control group. Secondly, the second solid tumor appears to have increased gene expression as ovarian cancer. The least expressed solid tumors are breast cancer. As for cancers that occur in the Blood, lymphoma has an upregulation expression. The lowest expression is CD80/CD86, which was in ALL. Conclusion: There is evidence that several cancer types and immune cells have expressed CD80 and CD86. This investigation demonstrated that the cell surface markers CD80/CD86 have a role in the progression of brain carcinomas.
Publication Details
Page(s) 127-130
Published Journal: Journal of Pioneering Medical Sciences, Volume: 13, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
CD80, brain cancer, CD86, immunological checkpoint proteins, solid tumors
References
Ibrahem S.,Ahmed H.,Zangana S. .2022 .Trends in colorectal cancer in Iraq over two decades: incidence, mortality, topography and morphology. Annals of Saudi Medicine, 42(4) : 252-261.
Peng S.,Bao Y. .2022 .A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy. Ann. Blood, 7 : 33.
Ahmed M. H.,Hernández-Verdin I.,Bielle F.,Verreault M.,Lerond J.,Alentorn A.,Idbaih A. .2023 .Expression and prognostic value of CD80 and CD86 in the tumor microenvironment of newly diagnosed glioblastoma. Canadian Journal of Neurological Sciences, 50(2) : 234-242.
Sato T.,Takagi K.,Higuchi M.,Abe H.,Kojimahara M.,Sagawa M.,Hojo H. .2022 .Immunolocalization of CD80 and CD86 in NonSmall Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. Acta Histochemica et Cytochemica, 55(1) : 25-35.
de Vos L.,Grünwald I.,Bawden E. G.,Dietrich J.,Scheckenbach K.,Wiek C.,Dietrich D. .2020 .The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas. Epigenetics, 15(11) : 1195-1212.
Liu W.,Xing J.,Tang X.,Sheng X.,Chi H.,Zhan W. .2022 .Characterization of Co-stimulatory ligand CD80/86 and its effect as a molecular adjuvant on DNA vaccine against Vibrio anguillarum in flounder (Paralichthys olivaceus). Frontiers in Immunology, 13 : 881753.
Lankipalli S.,Selvam M. S.,Samanta D.,Nair D.,Ramagopal D.,U. A. D. .2021 .Cryptic association of B7-2 molecules and its implication for clustering. Protein Science, 30(9) : 1958-1973.
Soskic B.,Jeffery L. E.,Kennedy A.,Gardner D. H.,Hou T. Z.,Halliday N.,Sansom D. M. .2021 .CD80 on human T Cells is associated with FoxP3 expression and supports treg homeostasis. Frontiers in Immunology, 11 : 577655.
Livak K. J.,Schmittgen T. D. .2001 .Analysis of relative gene expression data using real-time quantitative PCR and the 2-∆ CT method. Methods, 25(4) : 402-408.
Golubovskaya V. .2022 .CAR-T cells targeting immune checkpoint pathway players. Frontiers in Bioscience-Landmark, 27(4) : 121.
Arif K. B.,Said S.,Khiro N.,Ibrahem S.,Al-Ghamdi S. .2023 .Demographic and clinico-pathological characteristics of colorectal cancer in Kirkuk governorate. (Preprint), : 1-10.
Vackova J.,Polakova I.,Johari S. D.,Smahel M. .1935 .CD80 expression on tumor cells alters tumor microenvironment and efficacy of cancer immunotherapy by CTLA-4 blockade. , 13(8) : .
Zhang J.,Li S.,Liu F.,Yang K. .2022 .Role of CD68 in tumor immunity and prognosis prediction in pan-cancer. Scientific Reports, 12(1) : 7844.
Yu L.,Ding Y.,Wan T.,Deng T.,Huang H.,Liu J. .2021 .Significance of CD47 and its association with tumor immune microenvironment heterogeneity in ovarian cancer. Frontiers in Immunology, 12 : 768115.
Goux Le,Damotte C.,Vacher D.,Sibony S.,Delongchamps M.,Schnitzler N. B.,Pignot A.,G. A. .2017 .Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. In Urologic Oncology: Seminars and Original Investigations, 35(5) : 257-263.
Wang L.,Zhang C.,Zhang Z.,Shen B.,Li Z.,Zhang L.,Y. L. .2018 .Specific clinical and immune features of CD68 in glioma via 1,024 samples. Cancer Management and Research, 6409 : 6419.
Zhang Q.,Chen H.,Guo W.,Li Z.,Xu K.,Chen W. .2023 .CD86 Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression. Journal of Oncology, : .
0

Citations

0

Downloads

47

Views